MTVA MetaVia Inc.
Price Chart
Executive Summary
MetaVia presented new late-breaking Phase 1 data for DA-1726 (48 mg cohort) at ADA 2026, showing 9.1% mean body weight reduction at Day 54 with no plateau, and preclinical vanoglipel combination data demonstrating synergistic weight loss and hepatoprotective effects in MASH/T2D models. The data is clinically meaningful for a Phase 1 obesity asset but remains early-stage, with higher-dose Part 3 results expected in Q4 2026.
Actionable Insight
The 9.1% weight loss at Day 54 without plateau is a strong early signal for DA-1726, positioning it as a potentially competitive GLP1R/GCGR dual agonist. Monitor Q4 2026 higher-dose Part 3 results for durability and safety at higher exposures. Vanoglipel combination data adds optionality but remains preclinical. The stock may see near-term momentum from the ADA presentation, but clinical-stage biotech risk remains high.
Key Facts
- DA-1726 48 mg cohort achieved 9.1% mean body weight reduction at Day 54 (p<0.05 vs placebo at Day 26) with no evidence of plateau
- Waist circumference reduced by 9.8 cm at Day 54 (p<0.05 vs placebo)
- No treatment-related discontinuations or serious adverse events in the 48 mg cohort
- Vanoglipel + resmetirom combination achieved 23.6% body weight reduction vs control in preclinical MASH model (p<0.05)
- Vanoglipel + metformin reduced non-fasting glucose by 28.7% and body weight by 16.3% vs control (p<0.05)
- Higher-dose Part 3 titration study results expected in Q4 2026
Financial Impact
No financial data reported; market cap is $13M. Positive clinical data may drive valuation re-rating if DA-1726 continues to show competitive weight loss profile.
Risk Factors
- Data is from a small Phase 1 cohort (48 mg); larger and longer-term studies needed to confirm durability and safety
- No plateau observed yet, but follow-up is only through Week 8 — longer-term weight loss trajectory is unknown
- Vanoglipel data is preclinical; clinical validation in MASH/T2D is years away
- Company has a $13M market cap and likely needs to raise capital to fund ongoing trials
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-071211 |
| Document: mtva-20260608xex99d1.htm | 0001104659-26-071211 |
| Document: 0001104659-26-071211-index-headers.html | 0001104659-26-071211 |
| Document: 0001104659-26-071211-index.html | 0001104659-26-071211 |
| Document: 0001104659-26-071211.txt | 0001104659-26-071211 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
4d ago
|
8-K
| $2.22 awaiting T+5 | awaiting T+5 | — | $1.74 (−21.62%) |
|
Jun 8, 2026
5d ago
|
8-K
| $2.22 awaiting T+5 | awaiting T+5 | — | $1.74 (−21.62%) |
|
May 27, 2026
17d ago
|
8-K
| $3.34 $2.71 | ▼ −18.86% | ▼ −20.07% | $1.74 (−47.90%) |
|
May 18, 2026
26d ago
|
8-K
| $1.11 $2.97 | ▲ +167.57% | ▲ +165.95% | $1.74 (+56.76%) |
|
May 14, 2026
29d ago
|
8-K
| $1.11 $3.85 | ▲ +246.85% | ▲ +245.88% | $1.74 (+56.76%) |
|
Apr 10, 2026
9w ago
|
8-K
| $1.41 $1.40 | ▼ −0.71% | ▼ −5.21% | $1.74 (+23.40%) |
|
Apr 7, 2026
9w ago
|
EFFECT
| $1.21 $1.49 | ▲ +23.14% | ▲ +17.81% | $1.74 (+43.80%) |
|
Mar 18, 2026
12w ago
|
8-K
| $1.48 $1.30 | ▼ −12.16% | ▼ −11.45% | $1.74 (+17.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access